Top Stories
Bavarian Nordic monkeypox vaccine wins EU approval
Global Banking & Finance Review®
Company
OSLO (Reuters) – Danish biotechnology company Bavarian Nordic said on Monday the European Commission had given permission for its Imvanex vaccine to be marketed as protection against monkeypox, as recommended last week by the European Medicines Agency (EMA).
OSLO (Reuters) – Danish biotechnology company Bavarian Nordic said on Monday the European Commission had given permission for its Imvanex vaccine to be marketed as protection against monkeypox, as recommended last week by the European Medicines Agency (EMA).
The approval comes just one day after the World Health Organization issued a high-level alert declaring the rapidly spreading monkeypox outbreak as a global health emergency.
“The availability of an approved vaccine can significantly improve nations’ readiness to fight emerging diseases, but only through investments and structured planning of the biological preparedness,” Bavarian Chief Executive Paul Chaplin said.
Bavarian’s vaccine, the only one to have won approval for the prevention of monkeypox disease in the United States and Canada, has in the EU so far only been approved to treat smallpox.
But the company has supplied the vaccine to several EU countries during the current monkeypox outbreak for what is known as “off-label” use.
The approval is valid in all European Union Member States as well as in Iceland, Liechtenstein, and Norway, Bavarian Nordic said in a statement.
The development of Imvanex was made possible through significant investments from the U.S. government during the past two decades, the company added.
Bavarian’s share price has risen by 122% in the last three months, driven by strong demand for the monkeypox vaccine.
(Reporting by Terje Solsvik; Editing by Himani Sarkar and Kim Coghill)
The Imvanex vaccine is a vaccine developed by Bavarian Nordic that has been approved for use against monkeypox in the EU, following its previous approval for smallpox.
Monkeypox is a viral disease that causes symptoms similar to smallpox, including fever and rash. It is primarily found in Central and West Africa.
The EMA is responsible for evaluating and supervising medicinal products in the EU, ensuring they are safe and effective for public use.
Off-label use refers to the use of a vaccine for a purpose not specifically approved by regulatory authorities, often based on clinical judgment.
Explore more articles in the Top Stories category
